Description
Lapanix 250 MG (Lapatinib) is an orally administered dual HER1/HER2 tyrosine kinase inhibitor (TKI) and targeted oncology agent a small-molecule inhibitor that competitively blocks ATP binding at the intracellular kinase domains of both human epidermal growth factor receptor 1 (HER1/EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2), suppressing downstream RAS/RAF/MEK/ERK and PI3K/Akt/mTOR proliferative and survival signalling in HER2-overexpressing and EGFR-driven breast cancer cells, and providing intracellular kinase blockade that is mechanistically complementary to extracellular domain-targeting anti-HER2 monoclonal antibodies supplied as film-coated tablets in 250 mg strength in a 150-tablet pot and manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh.
Its active pharmaceutical ingredient, lapatinib INN (as lapatinib ditosylate), is indicated in combination with capecitabine for HER2-positive advanced or metastatic breast cancer in patients whose disease has progressed after prior therapy including an anthracycline, a taxane, and trastuzumab, and in combination with letrozole for postmenopausal women with HR+/HER2-positive metastatic breast cancer where chemotherapy is not intended as the initial therapy. Lapanix 250 MG film-coated tablets are administered at the standard lapatinib dose of 1,250 mg (five 250 mg tablets) once daily continuously in combination with capecitabine, or 1,500 mg (six 250 mg tablets) once daily continuously in combination with letrozole, with each 150-tablet pot supplying 30 days of therapy at the 1,250 mg/day dose.
The FDA approval of lapatinib in combination with capecitabine for HER2-positive advanced or metastatic breast cancer (March 2007) was supported by the Phase 3 EGF100151 trial (n=399), in which lapatinib plus capecitabine nearly doubled median time to progression (TTP) at 8.4 months versus 4.4 months with capecitabine alone (HR 0.49; p<0.001). In the HR+/HER2-positive metastatic setting combined with letrozole, the Phase 3 EGF30008 trial (n=219 in the HER2-positive subgroup) demonstrated a median progression-free survival (PFS) of 8.2 months versus 3.0 months with letrozole alone (HR 0.71; p=0.019). Important: Lapatinib carries risks of hepatotoxicity including fatal cases requiring liver function monitoring before initiation, every 4 to 6 weeks during treatment, and as clinically indicated; decreases in left ventricular ejection fraction (LVEF) have been reported, necessitating baseline and periodic cardiac assessment; severe diarrhoea, which can be life-threatening if not promptly managed, occurs in the majority of patients and requires proactive antidiarrhoeal therapy and dose adjustment guidance from the treating oncologist.
Searching for Lapanix 250 MG Lapatinib? Mediaid Pharmacy lists this product across its oncology medicines, breast cancer medicines, and Beacon Pharmaceuticals medicines portfolios and ships it worldwide.
Basic Product Information of Lapanix 250 MG (Lapatinib)
| Brand Name | Lapanix 250 MG (Lapatinib) |
| Product Name | Lapanix |
| Generic Name | Lapatinib INN (as lapatinib ditosylate; the ditosylate salt form is the pharmaceutical formulation used in all lapatinib tablets including Lapanix) |
| Drug Class | Targeted Oncology Agent; Dual HER1 (EGFR/ErbB1) and HER2 (ErbB2) Tyrosine Kinase Inhibitor (TKI); Reversible ATP-Competitive Intracellular Kinase Inhibitor; Small-Molecule HER-Family Inhibitor; Antineoplastic Agent |
| Formulation | Film-Coated Tablet (Oral) |
| Available Strengths | 250 mg lapatinib per film-coated tablet (equivalent to 398 mg lapatinib ditosylate per tablet; the 250 mg figure refers to lapatinib free base) |
| Available Pack Size | 150 tablets per pot (30-day supply at the standard lapatinib-capecitabine combination dose of 1,250 mg/day 5 tablets × 30 days = 150 tablets; or a 25-day supply at the lapatinib-letrozole combination dose of 1,500 mg/day 6 tablets × 25 days = 150 tablets) |
| Dosing Schedule | In combination with capecitabine (HER2+ advanced/metastatic breast cancer after prior trastuzumab and taxane): Lapatinib 1,250 mg (five Lapanix 250 MG tablets) orally once daily on Days 1–21 continuously, plus capecitabine 2,000 mg/m²/day orally in two divided doses approximately 12 hours apart on Days 1–14; repeated every 21 days. Take lapatinib at least 1 hour before or at least 1 hour after a meal; take all five tablets at the same time each day as a single daily dose do not divide the dose.
In combination with letrozole (HR+/HER2+ metastatic breast cancer; postmenopausal; no intended initial chemotherapy): Lapatinib 1,500 mg (six Lapanix 250 MG tablets) orally once daily continuously, plus letrozole 2.5 mg orally once daily continuously. Take lapatinib at least 1 hour before or at least 1 hour after a meal. Continue until disease progression or unacceptable toxicity. Consult the treating oncologist for dose modification guidance for diarrhoea, hepatotoxicity, cardiac toxicity, or drug interactions. |
| Primary Indications | (1) HER2-Positive Advanced or Metastatic Breast Cancer In Combination with Capecitabine: Lapatinib in combination with capecitabine for the treatment of patients with HER2-positive advanced or metastatic breast cancer whose disease has progressed after prior therapy that included an anthracycline, a taxane, and trastuzumab. (FDA approval: March 13, 2007; based on Phase 3 EGF100151 trial.)
(2) HR-Positive/HER2-Positive Metastatic Breast Cancer In Combination with Letrozole: Lapatinib in combination with letrozole for the treatment of postmenopausal women with HR-positive/HER2-positive metastatic breast cancer for whom hormonal therapy is indicated. (FDA approval: January 29, 2010; based on Phase 3 EGF30008 trial.) |
| Originator Reference Brand | Tykerb® (United States; GlaxoSmithKline/Novartis; lapatinib ditosylate 250 mg tablets; first FDA approval March 13, 2007 for HER2+ advanced/metastatic breast cancer in combination with capecitabine; subsequently approved January 29, 2010 for HR+/HER2+ metastatic breast cancer in combination with letrozole) / Tyverb® (European Union and rest of world). Both Lapanix and Tykerb®/Tyverb® contain lapatinib INN (as lapatinib ditosylate) at 250 mg lapatinib free base per tablet in the same dual HER1/HER2 TKI drug class. Lapanix is manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh and is supplied through Mediaid Pharmacy for international procurement. |
| Manufacturer | Beacon Pharmaceuticals Ltd., Bangladesh |
| Country of Origin | Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at room temperature 15°C to 30°C (59°F to 86°F). Keep in the original pot with the lid tightly closed. Protect from moisture and light. Keep out of the reach of children. |
How Lapanix (Lapatinib) Works: Dual HER1/HER2 Intracellular Kinase Inhibition, Downstream Signalling Suppression, and Tumour Cell Cycle Arrest in HER2+ Breast Cancer
Lapatinib INN is an orally administered targeted oncology agent whose mechanism of action is mechanistically distinct from anti-HER2 monoclonal antibodies (trastuzumab, pertuzumab), antibody-drug conjugates (trastuzumab emtansine, trastuzumab deruxtecan), CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), mTOR inhibitors (everolimus), and all other antineoplastic drug classes in clinical breast cancer use: lapatinib is a selective, reversible, ATP-competitive, small-molecule inhibitor of two co-expressed HER family receptor tyrosine kinases HER1 (EGFR/ErbB1) and HER2 (ErbB2) that simultaneously blocks the intracellular kinase domain ATP-binding pockets of both receptors at the 4-anilinoquinazoline pharmacophore binding site, preventing receptor autophosphorylation and transphosphorylation of HER family receptor homodimer and heterodimer complexes on the inner leaflet of the cell membrane.
HER2 (human epidermal growth factor receptor 2) is a transmembrane receptor tyrosine kinase that is overexpressed in approximately 15–20% of breast cancers due to HER2 gene amplification at chromosomal locus 17q12, and whose constitutive kinase activation drives the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) proliferative signalling cascade and the PI3K/Akt/mTOR cell survival pathway in HER2-overexpressing tumour cells. HER1 (EGFR) is co-expressed on the surface of HER2-amplified breast cancer cells and participates in HER2 heterodimer formation, contributing additional oncogenic kinase signalling that lapatinib’s dual-target inhibition addresses simultaneously a mechanistic advantage over purely HER2-selective strategies in cells where HER1 co-activation contributes to HER2-driven tumour growth.
Lapatinib binds within the ATP-binding cleft of both HER1 and HER2 kinase domains in their inactive conformation, occupying the site normally engaged by ATP and thereby preventing the phosphate-transfer step required for receptor autophosphorylation, substrate phosphorylation, and downstream kinase cascade activation. By blocking HER1 and HER2 kinase phosphorylation simultaneously, lapatinib disrupts the formation of catalytically active HER1/HER2 heterodimers the most oncogenically potent HER family signalling unit in HER2-amplified breast cancers and suppresses phosphorylation of the downstream effector proteins ERK1/2 and Akt, reducing cell cycle progression signals and promoting G1 phase arrest and apoptosis in HER2-overexpressing breast cancer cell lines.
A clinically significant mechanistic feature of lapatinib’s intracellular mode of action is its ability to remain pharmacologically active in the presence of truncated forms of HER2 (p95-HER2): a common acquired resistance mechanism to trastuzumab involves proteolytic cleavage of the trastuzumab-accessible HER2 extracellular domain, generating membrane-bound p95-HER2 fragments that retain intact intracellular kinase activity but lack the subdomain IV epitope to which trastuzumab binds. Because lapatinib acts at the intracellular kinase domain rather than the extracellular antibody-binding site, lapatinib retains full kinase-inhibitory activity against p95-HER2 truncations the pharmacological rationale for lapatinib’s residual activity in a subset of trastuzumab-resistant HER2-positive tumours in the clinical EGF100151 setting.
Lapatinib’s reversible kinase inhibition in contrast to the irreversible covalent inhibition of pan-HER TKIs such as neratinib and afatinib means that kinase re-occupancy by ATP can resume when lapatinib plasma concentrations fall below the inhibitory threshold, which is the pharmacological basis for lapatinib’s once-daily continuous dosing regimen at the highest tolerated dose to maintain sustained HER1/HER2 suppression throughout the 24-hour dosing cycle. The food effect on lapatinib pharmacokinetics is clinically significant and dose-management-critical: administration with a high-fat meal increases lapatinib area under the concentration-time curve (AUC) by up to 3.5-fold and maximum plasma concentration (Cmax) by up to 2.7-fold compared with fasting administration, creating an unacceptable risk of concentration-dependent toxicities particularly diarrhoea and cardiac QTc prolongation if meal composition at the time of tablet intake varies unpredictably between doses. The prescribing recommendation to administer Lapanix at least 1 hour before or 1 hour after food is therefore not a preference but a pharmacokinetically driven safety requirement for consistent and predictable lapatinib plasma exposure across the treatment course.
Clinical Safety Profile of Lapanix 250 MG (Lapatinib)
| Serious Warnings and Precautions | Hepatotoxicity: Severe hepatotoxicity, including fatal cases, has been reported with lapatinib therapy. Monitor liver function tests (LFTs: ALT, AST, bilirubin) before initiating Lapanix, every 4 to 6 weeks during the first 6 months of treatment, and as clinically indicated thereafter. Discontinue Lapanix permanently in patients who develop Grade 3 or greater hepatotoxicity; do not re-initiate lapatinib in patients who experienced Grade 3 or greater hepatic events.
Decreased Left Ventricular Ejection Fraction (LVEF): Lapatinib has been associated with decreases in LVEF that may be symptomatic (cardiac failure). Assess LVEF in all patients before initiating Lapanix and at regular intervals during treatment. Interrupt Lapanix if LVEF falls below the institution’s lower limit of normal (LLN) or if the patient develops symptomatic cardiac dysfunction; discontinue permanently for confirmed Grade 3 or 4 LVEF reduction. QTc Prolongation: Lapatinib prolongs the QTc interval in a concentration-dependent manner. Avoid co-administration with medicines known to prolong QTc. Correct electrolyte abnormalities (hypokalaemia, hypomagnesaemia) before and during Lapanix therapy. Monitor ECG and QTc in patients at risk. Severe Diarrhoea: Diarrhoea occurs in the majority of patients receiving lapatinib, including Grade 3 events in approximately 13% of patients. Initiate antidiarrhoeal treatment (loperamide) at the first sign of bowel loosening; maintain adequate oral hydration; interrupt or reduce Lapanix dose for Grade 3 or Grade 4 diarrhoea or Grade 1–2 diarrhoea not controlled with antidiarrhoeal therapy. |
| Common Adverse Reactions | In patients receiving lapatinib plus capecitabine (EGF100151): diarrhoea, palmar-plantar erythrodysesthesia syndrome (PPES/hand-foot syndrome), nausea, rash, vomiting, fatigue, stomatitis, extremity pain, and constipation. Diarrhoea was the most common adverse event: all-grade diarrhoea occurred in 65% of lapatinib-capecitabine patients; Grade 3 diarrhoea in 13%. Palmar-plantar erythrodysesthesia (PPE/hand-foot syndrome) a capecitabine class effect occurred in all grades in 53% of patients. The acneiform/maculopapular rash associated with lapatinib’s EGFR (HER1) inhibition occurred in approximately 27% of patients; Grade 3 rash in 2%. In patients receiving lapatinib plus letrozole (EGF30008, HER2-positive subgroup): diarrhoea, rash, nausea, arthralgia, fatigue, and hot flushes. Grade 3/4 events in the lapatinib arm: diarrhoea (Grade 3: ~13%), elevated liver function tests (Grade 3: ~5–8% for ALT/AST), and rash (Grade 3: ~2%). LVEF decreases (all grades, including asymptomatic) occurred in approximately 2% of patients. Pulmonary toxicity including ILD and pneumonitis has been reported in a small proportion of patients receiving lapatinib. |
| Drug Interactions | Lapatinib is primarily metabolised by CYP3A4 (major) and CYP3A5 and CYP2C8 (minor); lapatinib is also a substrate and inhibitor of P-glycoprotein (P-gp) and BCRP efflux transporters, and a weak CYP3A4 and CYP2C8 inhibitor. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, grapefruit juice): markedly increase lapatinib plasma AUC (up to 3.6-fold with ketoconazole) and substantially increase the risk of QTc prolongation, hepatotoxicity, and diarrhoea avoid concurrent use; if unavoidable, reduce Lapanix dose to 500 mg/day and monitor closely. Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, dexamethasone, St John’s Wort): significantly reduce lapatinib plasma exposure and may compromise efficacy avoid concurrent use; if unavoidable, titrate lapatinib dose upward to a maximum of 4,500 mg/day (capecitabine combination) or 5,500 mg/day (letrozole combination) under specialist guidance and with mandatory LFT monitoring. QTc-prolonging agents (sotalol, amiodarone, ondansetron, haloperidol, quinolone antibiotics): additive risk of QTc prolongation avoid or monitor ECG closely. Food interaction: high-fat meals dramatically increase lapatinib AUC (up to 3.5-fold) administer Lapanix consistently in a fasted state at least 1 hour before or 1 hour after food. Disclose all concomitant medications to the treating oncologist before initiating Lapanix. |
| Pregnancy & Lactation | Based on its mechanism of action as a dual HER1/HER2 kinase inhibitor and animal reproductive toxicology data, lapatinib may cause embryo-foetal harm when administered during pregnancy. No adequate and well-controlled human pregnancy studies exist. Lapanix should not be used during pregnancy unless the potential benefit to the patient clearly outweighs the risk to the foetus, under explicit specialist risk-benefit assessment and documentation. Females of reproductive potential must use effective contraception during Lapanix therapy and for at least 1 week after the final dose. Verify pregnancy status with a serum or urine test before initiating Lapanix in females of reproductive potential. Male patients with female partners of reproductive potential should use effective contraception during treatment. Note that lapatinib in combination with capecitabine is subject to capecitabine’s additional reproductive warnings capecitabine is contraindicated during pregnancy (cytotoxic teratogen) and requires at least 6 months of post-treatment contraception in both males and females after capecitabine discontinuation; the capecitabine contraceptive requirement supersedes lapatinib’s 1-week washout in this combination regimen. It is not known whether lapatinib or its metabolites are excreted in human breast milk; breastfeeding is not recommended during Lapanix treatment and for at least 1 week after the final dose. Discuss all reproductive planning, contraceptive requirements, and fertility considerations with the treating oncologist before and throughout Lapanix therapy. |
Who Should Use Lapanix 250 MG (Lapatinib)?
Lapanix (Lapatinib) is indicated across two biologically distinct settings of HER2-positive breast cancer, both defined by confirmed HER2 protein overexpression (IHC 3+) or HER2 gene amplification (by FISH or validated in situ hybridisation) as a mandatory eligibility requirement, with the two indications addressing clinically separate patient populations heavily pre-treated metastatic HER2-positive disease and hormone receptor co-positive HER2-amplified metastatic disease where lapatinib’s unique intracellular dual kinase inhibition provides a mechanistically distinct and evidence-based treatment strategy.
First, patients with HER2-positive advanced or metastatic breast cancer whose disease has progressed after prior therapy including an anthracycline, a taxane, and trastuzumab represent the primary approved indication for Lapanix in combination with capecitabine: the Phase 3 EGF100151 trial (n=399; lapatinib 1,250 mg/day plus capecitabine 2,000 mg/m²/day versus capecitabine alone) demonstrated that adding lapatinib to capecitabine nearly doubled the median time to progression (TTP) from 4.4 months to 8.4 months (HR 0.49; 95% CI 0.34–0.71; p<0.001), with a 51% reduction in the risk of disease progression. The overall response rate (ORR) was 22% with lapatinib plus capecitabine versus 14% with capecitabine alone. Critically, the EGF100151 trial enrolled patients with HER2-positive disease who had progressed on trastuzumab establishing lapatinib as an active treatment in the trastuzumab-refractory setting and providing evidence for the value of continued HER2 blockade via a non-overlapping intracellular mechanism after trastuzumab progression. Central nervous system (CNS) metastases are present in approximately 25–35% of HER2-positive metastatic breast cancer patients; lapatinib’s small-molecule structure enables blood-brain barrier penetration at clinically active concentrations, and retrospective and prospective data (LANDSCAPE trial with lapatinib-capecitabine) support activity in HER2+ brain metastases, a patient population where monoclonal antibody-based HER2 therapies have limited CNS penetration.
Second, postmenopausal women with HR-positive/HER2-positive metastatic breast cancer for whom endocrine-based therapy is the preferred initial approach over chemotherapy represent the EGF30008-based lapatinib-letrozole indication: in the HER2-positive subgroup of EGF30008 (n=219), lapatinib 1,500 mg/day plus letrozole 2.5 mg/day demonstrated a median PFS of 8.2 months versus 3.0 months with letrozole alone (HR 0.71; p=0.019), reflecting the clinical importance of simultaneously blocking HER2-driven crosstalk signalling that reduces endocrine sensitivity in HR+/HER2+ co-positive tumours. Lapanix is not appropriate in HER2-negative or HER2-low breast cancer without confirmed overexpression or amplification; in patients with severe hepatic impairment requiring full-dose lapatinib (dose reduction and increased LFT monitoring are required in moderate hepatic impairment); in patients with a baseline QTc >480 ms or pre-existing uncorrected electrolyte abnormalities; or in patients unable to adhere to the fasted administration requirement who cannot maintain consistent dosing conditions.
HER2-positive breast oncology departments, medical oncology teams managing trastuzumab-refractory metastatic breast cancer, hospital formulary and procurement teams in regions where Tykerb®/Tyverb® accessibility or pricing is a barrier, and patients and families sourcing affordable lapatinib therapy can browse the Mediaid Pharmacy breast cancer medicines portfolio, the oncology medicines collection, and the Beacon Pharmaceuticals medicines range for the complete selection available with worldwide delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Lapanix 250 MG (Lapatinib)
Mediaid Pharmacy is a Dhaka-based supplier of specialty targeted oncology, breast cancer, and rare disease medicines with worldwide shipping to patients, HER2-positive breast oncology departments, trastuzumab-refractory metastatic breast cancer treatment programmes, hospital pharmacies, and international distributors across all regions. Lapanix (Lapatinib), manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh, is supplied as 250 mg film-coated tablets in a 150-tablet pot with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order.
The 150-tablet pot format provides a clinically practical supply unit: at the standard lapatinib-capecitabine combination dose of 1,250 mg/day (five tablets once daily), one 150-tablet pot covers a complete 30-day continuous treatment period; at the lapatinib-letrozole combination dose of 1,500 mg/day (six tablets once daily), one pot covers 25 days of lapatinib treatment, allowing pharmacy teams to plan capecitabine and letrozole co-prescription supply quantities accurately alongside Lapanix.
HER2-positive breast cancer treatment centres and academic oncology programmes managing patients with advanced or metastatic disease after prior trastuzumab and taxane therapy; oncology departments treating postmenopausal HR+/HER2+ metastatic breast cancer patients preferring an oral endocrine-based treatment approach; hospital oncology formulary and procurement teams seeking a more accessible-priced lapatinib option relative to Tykerb®; international oncology patient access programmes; and individual patients and families seeking breast cancer medicines including lapatinib tablets for HER2-positive metastatic breast cancer can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all enquiries regarding Lapanix Lapatinib stock availability, current pricing, and international delivery timelines.
Procurement teams co-sourcing Lapanix with other Beacon Pharmaceuticals oncology generics or targeted breast cancer medicines can browse the complete Mediaid Pharmacy oncology medicines collection and the Beacon Pharmaceuticals medicines portfolio before requesting a consolidated quotation.
Why Choose Lapanix 250 MG (Lapatinib) from Mediaid Pharmacy?
Lapanix (Lapatinib) provides HER2-positive breast oncologists and metastatic breast cancer treatment teams with a Phase 3-validated, orally administered dual HER1/HER2 TKI whose intracellular ATP-competitive kinase inhibition mechanism is pharmacologically distinct from every other HER2-targeted agent in breast cancer clinical practice including extracellular-domain-targeting monoclonal antibodies (trastuzumab, pertuzumab), antibody-drug conjugates (trastuzumab emtansine, trastuzumab deruxtecan), and irreversible pan-HER TKIs (neratinib, afatinib, tucatinib) providing a mechanistically justified treatment option in trastuzumab-refractory HER2+ metastatic breast cancer and in HR+/HER2+ co-positive disease where HER2 signalling suppresses endocrine sensitivity.
The clinical evidence base supporting lapatinib’s therapeutic value is anchored in two Phase 3 randomised trials. The EGF100151 trial (n=399) established lapatinib-capecitabine as an active regimen in trastuzumab-pre-treated HER2+ metastatic breast cancer, demonstrating a near-doubling of median TTP (8.4 versus 4.4 months; HR 0.49; p<0.001), earning lapatinib the first-ever FDA approval for a HER2-positive metastatic breast cancer indication beyond first-line trastuzumab-based therapy in March 2007 and establishing it as the reference comparator arm against which subsequent HER2 TKIs and ADCs (including trastuzumab emtansine in the EMILIA trial) were evaluated.
The EGF30008 trial (n=219 in the HER2+ subgroup) extended lapatinib’s clinical utility to the HR+/HER2+ metastatic setting a biologically distinct subgroup accounting for approximately 50% of all HER2-positive breast cancers by demonstrating that adding lapatinib to letrozole extended median PFS by 5.2 months (8.2 versus 3.0 months; HR 0.71; p=0.019) and improved ORR (28% versus 15%), establishing the clinical principle that dual HER2 blockade substantially rescues endocrine therapy sensitivity in HR+/HER2+ tumours where HER2 signalling constitutively activates ER-independent proliferative pathways that letrozole alone cannot suppress.
A clinically important and practically differentiating attribute of lapatinib versus anti-HER2 monoclonal antibodies is its blood-brain barrier penetrability: lapatinib’s small lipophilic molecule structure enables CNS penetration at pharmacologically active concentrations, providing treatment options in HER2+ metastatic breast cancer patients with brain metastases a high-risk subgroup representing 25–35% of the HER2+ metastatic breast cancer population where biologic HER2 agents have limited CNS activity and local radiation therapy has inherent long-term neurocognitive risks.
The oral once-daily administration of Lapanix at 1,250 mg or 1,500 mg provides the convenience of a fully outpatient HER2-targeted therapy regimen, eliminating the infusion centre dependency, chair time, and institutional administration cost associated with IV HER2 biologics, particularly important for patients in lower-resource healthcare settings or those seeking to maintain independent daily function during cancer therapy.
Lapanix is manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh and is available through Mediaid Pharmacy as 250 mg film-coated tablets in a 150-tablet pot with full product documentation, specialist supply coordination, and worldwide shipping from Dhaka. To source additional Beacon Pharmaceuticals oncology medicines, visit the Mediaid Pharmacy Beacon Pharmaceuticals medicines section and the breast cancer medicines portfolio, and contact the team for a personalised quotation.
Frequently Asked Questions About Lapanix 250 MG (Lapatinib)
What is Lapanix 250 MG (Lapatinib) used for?
Lapanix 250 MG (Lapatinib) is an orally administered dual HER1/HER2 tyrosine kinase inhibitor (TKI) indicated for two settings of HER2-positive breast cancer: (1) in combination with capecitabine for the treatment of patients with HER2-positive advanced or metastatic breast cancer whose disease has progressed after prior therapy including an anthracycline, a taxane, and trastuzumab (Phase 3 EGF100151: median TTP 8.4 vs 4.4 months; HR 0.49; FDA approval March 2007); and (2) in combination with letrozole for the treatment of postmenopausal women with HR-positive/HER2-positive metastatic breast cancer for whom hormonal therapy is preferred over initial chemotherapy (Phase 3 EGF30008 HER2+ subgroup: median PFS 8.2 vs 3.0 months; HR 0.71; FDA approval January 2010). Lapatinib acts by simultaneously blocking the intracellular kinase domains of both HER1 (EGFR) and HER2, suppressing the RAS/MAPK and PI3K/Akt proliferative signalling pathways in HER2-overexpressing tumour cells. The originator brand is Tykerb® (US) / Tyverb® (EU), developed by GlaxoSmithKline. Lapanix is manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh and is available through Mediaid Pharmacy with worldwide shipping as 250 mg film-coated tablets in 150-tablet pots.
What is the generic name of Lapanix?
The generic name of Lapanix is lapatinib INN, formulated as lapatinib ditosylate the pharmaceutically stable p-toluenesulfonate salt form used in all lapatinib tablet formulations including the originator Tykerb®/Tyverb® and the Beacon Pharmaceuticals Lapanix product. The 250 mg strength refers to 250 mg of lapatinib free base per tablet (equivalent to approximately 398 mg of lapatinib ditosylate). Lapanix is the brand name registered by Beacon Pharmaceuticals Ltd. (Bangladesh) for its lapatinib 250 mg film-coated tablet. The originator brand, Tykerb® (lapatinib ditosylate tablets 250 mg; GlaxoSmithKline/Novartis), received its initial FDA approval on March 13, 2007 for HER2-positive advanced or metastatic breast cancer in combination with capecitabine the first orally administered HER2-targeted TKI to receive FDA approval in breast cancer. Mediaid Pharmacy distributes Lapanix (Lapatinib) 250 MG globally with worldwide shipping to patients, breast oncology clinics, hospital pharmacies, and HER2-positive breast cancer treatment programmes.
What is the difference between Lapanix (Lapatinib), Tukysa (Tucatinib), and Nerlynx (Neratinib)?
Lapatinib (Lapanix), tucatinib (Tukysa), and neratinib (Nerlynx/Neratinib) are all small-molecule HER-family tyrosine kinase inhibitors used in HER2-positive breast cancer but differ substantially in kinase selectivity, binding mechanism, approved indications, and CNS activity. Lapatinib is a reversible dual HER1/HER2 inhibitor approved in second-line HER2+ metastatic breast cancer (lapatinib-capecitabine) and first-line HR+/HER2+ metastatic breast cancer (lapatinib-letrozole). Tucatinib (Tukysa) is a highly selective, reversible HER2-only TKI (minimal HER1/EGFR inhibition), approved in combination with trastuzumab and capecitabine for HER2+ metastatic breast cancer (including patients with brain metastases) based on the HER2CLIMB trial (mPFS 7.8 vs 5.6 months; HR 0.54; OS benefit confirmed), and is generally considered the preferred oral HER2 TKI for patients with active CNS metastases in current ESMO/ASCO guidelines. Neratinib (Nerlynx) is an irreversible pan-HER TKI (HER1, HER2, HER4) approved for extended adjuvant treatment of HER2-positive early breast cancer after trastuzumab-based adjuvant therapy (ExteNET trial: 2-year iDFS 94.2% vs 91.9%), and in combination with capecitabine for third-line or later HER2+ metastatic breast cancer (NALA trial). Key differentiators: lapatinib’s dual HER1 inhibition produces the acneiform EGFR-class rash and diarrhoea profile; tucatinib’s HER2 selectivity produces a cleaner tolerability profile with less diarrhoea than lapatinib; neratinib’s irreversible binding produces substantially higher rates of diarrhoea (Grade 3 in ~40% without prophylaxis) requiring mandatory loperamide prophylaxis. For the full range of HER2-targeted breast cancer medicines, visit the Mediaid Pharmacy breast cancer medicines collection.
How is Lapanix 250 MG (Lapatinib) administered?
Lapanix film-coated tablets are administered orally, once daily, as a single daily dose all tablets are taken together at one time, not divided across the day. The standard dose with capecitabine is 1,250 mg (five Lapanix 250 MG tablets) once daily; the standard dose with letrozole is 1,500 mg (six Lapanix 250 MG tablets) once daily. Lapanix must be taken on an empty stomach: administer at least 1 hour before or at least 1 hour after a meal. Taking lapatinib with food particularly high-fat food significantly and unpredictably increases lapatinib plasma exposure, creating a substantial risk of concentration-dependent toxicity including severe diarrhoea, cardiac QTc prolongation, and hepatotoxicity if food composition varies between doses. Swallow Lapanix tablets whole; do not crush, break, or chew them. Take Lapanix at approximately the same time each day to maintain consistent plasma lapatinib concentrations. If a dose is missed, skip the missed dose and take the next scheduled dose at the regular time; do not double the next dose. In the lapatinib-capecitabine combination, capecitabine is taken twice daily with food (morning and evening) on Days 1–14 of each 21-day cycle, while lapatinib is taken once daily on all 21 days of each cycle; patients must understand that lapatinib and capecitabine have different administration timing requirements relative to meals. All dose modifications reductions to 1,000 mg/day for Grade 3 diarrhoea or cardiac toxicity must be directed by the treating oncologist.
What are the side effects of Lapanix 250 MG (Lapatinib)?
The most clinically significant and prevalent adverse effects of lapatinib (Lapanix) are diarrhoea, hepatotoxicity (elevated liver enzymes), dermatological reactions (acneiform rash from HER1/EGFR inhibition), and decreased LVEF. Diarrhoea is the dominant dose-limiting adverse event: all-grade diarrhoea occurs in approximately 65% of patients on lapatinib-capecitabine; Grade 3 diarrhoea requiring dose modification or hospitalisation occurs in approximately 13% of patients. Diarrhoea typically begins within the first week of treatment; proactive loperamide initiation at the first sign of loose stools and adequate hydration are the standard management strategy. Palmar-plantar erythrodysesthesia (PPE/hand-foot syndrome) is a prominent additional toxicity in the lapatinib-capecitabine combination, attributable to capecitabine rather than lapatinib itself; the acneiform maculopapular rash on the face, scalp, chest, and upper back is an EGFR (HER1) class effect of lapatinib occurring in approximately 27–44% of patients (Grade 3: ~2%). Hepatotoxicity manifest as Grade 3/4 ALT or AST elevations occurs in approximately 5–8% of patients; rare fatal hepatic cases have been reported; LFT monitoring every 4 to 6 weeks during the first 6 months of therapy is mandatory. Cardiac LVEF decrease of any grade occurs in approximately 1–2% of lapatinib-treated patients; assessment is required at baseline and periodically during treatment. Pulmonary toxicity (ILD/pneumonitis) has been reported in a small proportion of patients. Common non-serious adverse events include nausea, vomiting, fatigue, stomatitis, and extremity pain. Always manage Lapanix therapy under the supervision of an experienced oncologist with structured diarrhoea, LFT, and cardiac monitoring throughout treatment.
How effective is Lapatinib (Lapanix) for HER2-positive metastatic breast cancer?
Lapatinib has demonstrated clinically significant and statistically confirmed efficacy across its two approved indications in two Phase 3 randomised controlled trials. In the EGF100151 trial (n=399; lapatinib plus capecitabine versus capecitabine alone in HER2+ advanced/metastatic breast cancer after prior anthracycline, taxane, and trastuzumab) the independent review committee-assessed median time to progression (TTP) was 8.4 months with lapatinib-capecitabine versus 4.4 months with capecitabine alone (HR 0.49; 95% CI 0.34–0.71; p<0.001) a 51% reduction in the risk of disease progression with an ORR of 22% versus 14% in patients with measurable disease, and a clinically meaningful reduction in CNS-only recurrence as first site of progression (2 events versus 11 events; p=0.045) in the lapatinib arm, supporting lapatinib’s CNS activity in HER2+ metastatic breast cancer. In the EGF30008 trial HER2-positive subgroup (n=219; lapatinib 1,500 mg/day plus letrozole versus letrozole alone in postmenopausal HR+/HER2+ metastatic breast cancer), the median PFS was 8.2 months versus 3.0 months (HR 0.71; 95% CI 0.53–0.96; p=0.019), ORR 28% versus 15%, and clinical benefit rate (CR+PR+SD ≥24 weeks) 48% versus 29% confirming that dual HER1/HER2 kinase inhibition with lapatinib substantially improves outcomes in the biologically important HR+/HER2+ co-positive metastatic subgroup where HER2-driven endocrine resistance is the primary mechanism of letrozole failure. These findings established lapatinib as the first orally administered HER2 TKI to demonstrate Phase 3 survival benefit in advanced breast cancer and define its role in the HER2-positive metastatic breast cancer treatment landscape. Lapanix delivers lapatinib INN at 250 mg per film-coated tablet, sourced through Mediaid Pharmacy with worldwide shipping. Visit the oncology medicines collection for the full targeted therapy range.
Is Lapanix 250 MG (Lapatinib) safe during pregnancy or while breastfeeding?
Based on its mechanism of action and animal reproductive toxicology data, lapatinib may cause embryo-foetal harm when administered during pregnancy; adequate and well-controlled human pregnancy studies are not available. Lapanix should not be used during pregnancy. Females of reproductive potential must use effective contraception during Lapanix therapy and for at least 1 week after the final dose. When Lapanix is prescribed in combination with capecitabine, the capecitabine-specific contraception requirement at least 6 months of effective contraception after capecitabine discontinuation for females and males supersedes lapatinib’s shorter 1-week washout period; the combined regimen contraception period is therefore governed by capecitabine’s reproductive toxicity guidance. Verify pregnancy status before initiating Lapanix in females of reproductive potential. It is not known whether lapatinib or its metabolites are present in human breast milk; breastfeeding is not recommended during Lapanix treatment and for at least 1 week after the final dose due to the potential for serious adverse reactions in the nursing infant. Discuss all reproductive planning, contraceptive requirements, and fertility considerations including the separate and potentially longer contraceptive obligations associated with capecitabine co-therapy explicitly with the treating oncologist before and throughout Lapanix therapy.
Can I order Lapanix 250 MG (Lapatinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Lapanix 250 MG (Lapatinib) 150 film-coated tablets per pot, manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh to patients, HER2-positive breast oncology and medical oncology departments, HR+/HER2+ metastatic breast cancer treatment centres, hospital pharmacies, oncology patient access programmes, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order Lapanix 250 MG (Lapatinib) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com




Reviews
There are no reviews yet.